financetom
Business
financetom
/
Business
/
Phillips 66 Appoints Chief Executive Mark Lashier as Chairman of Board
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Phillips 66 Appoints Chief Executive Mark Lashier as Chairman of Board
Mar 12, 2024 2:59 PM

05:37 PM EDT, 03/12/2024 (MT Newswires) -- Phillips 66 (PSX) said Tuesday that its board appointed President and Chief Executive Mark Lashier as chairman of the board.

Lashier's appointment as chairman will become effective immediately before the annual meeting of shareholders on May 15, according to the company.

Current Executive Chairman Greg Garland will step down from the board and the number of directors will be reduced to 13 from 14, Phillips added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AutoCanada Closes Second Credit Facility Amendment
AutoCanada Closes Second Credit Facility Amendment
Dec 30, 2024
07:11 AM EST, 12/30/2024 (MT Newswires) -- AutoCanada ( AOCIF ) on Monday said it has closed a second amendment to its credit facility with Scotiabank (BNS.TO) and other lenders. Key terms include lender approval to amend the definition of EBITDA to include add-backs of up to $35 million for specific one-time expenses, including US$20 million provisioned for Federal Trade...
High Tide to Expand in European Cannabis Market in Early 2025
High Tide to Expand in European Cannabis Market in Early 2025
Dec 30, 2024
07:10 AM EST, 12/30/2024 (MT Newswires) -- High Tide (Nasdaq and TSXV: HITI) on Monday said it will expand further in the European cannabis market early next year after its recent rollout of the Cabana Club membership program in the U.S. and Europe showed encouraging results. The Cabana Club continues to be our crown jewel, now boasting over 1.55 million...
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study
Dec 30, 2024
Dec 30 (Reuters) - Axsome Therapeutics ( AXSM ) said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial. ...
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study
Dec 30, 2024
07:12 AM EST, 12/30/2024 (MT Newswires) -- Novartis ( NVS ) said in a regulatory filing Monday that its phase 3 study evaluating its one-time gene therapy intrathecal onasemnogene abeparvovec, or OAV101 IT, met its primary endpoint. Based on the results, there was an increase from baseline in the Hammersmith Functional Motor Scale - Expanded, or HFMSE, total score in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved